Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals

DelveInsight's "Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Nonalcoholic Steatohepatitis (NASH) Market is poised for growth in the upcoming years, driven by the rising incidence of NASH in the 7MM (Seven Major Markets) and the forthcoming introduction of innovative therapies.

Global companies are actively engaged in the development of novel treatment modalities, achieving significant progress over time. Among the prominent contributors to drug development for Non-Alcoholic Steatohepatitis are Inventiva Pharma, Novo Nordisk, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Inc., and others.

The current pipeline of NASH consists of plenty of drugs. FXR Agonists, FGF21 Stimulants, FGF19 Analog, Glucagon-like Peptide-1 (GLP-1) Agonist, Peroxisome Proliferator-activated Receptor (PPAR) Regulators, THR- Agonist, and some others are the most highlighted class of this indication. Ongoing research and current trials can potentially change the Nonalcoholic Steatohepatitis (NASH) treatment scenario in the coming years.

DelveInsight's "Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast 2032 [https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Nonalcoholic Steatohepatitis (NASH) market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Nonalcoholic Steatohepatitis (NASH) market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Nonalcoholic Steatohepatitis (NASH) Overview

Non-alcoholic fatty liver disease (NAFLD) serves as a comprehensive term encompassing the entire spectrum of fatty liver conditions, ranging from simple steatosis to more advanced stages involving hepatitis, fibrosis, cirrhosis, and, in severe instances, hepatocellular carcinoma.

Within the NAFLD spectrum, Nonalcoholic Steatohepatitis (NASH) represents the progressive form of liver injury, posing risks of advancing fibrosis, cirrhosis, and eventual liver failure. This prevalent chronic liver ailment is characterized by liver inflammation and damage induced by fat accumulation. Children, under certain unhealthy conditions, may also develop NAFLD and NASH, mirroring occurrences in adults. The precise reasons behind why some children with NAFLD develop simple fatty liver while others progress to NASH remain unclear.

Treatment for NASH lacks a standardized approach; however, lifestyle modifications have demonstrated efficacy in influencing disease progression. These lifestyle adjustments may entail weight loss, adhering to a balanced diet, and managing underlying health conditions such as hypothyroidism and diabetes. In cases where NASH coexists with cirrhosis, treatment may involve medications and potentially surgical interventions. Individuals with NASH complications, such as liver cancer or liver failure, may necessitate liver transplantation.

Nonalcoholic Steatohepatitis (NASH) Market Key Facts

*
In the US, there were approximately 20 million prevalent cases of NASH in 2021, which is anticipated to rise by 2032.

*
In 2021, 57% of males and around 43% of females were found to be affected by NASH in the US.

*
According to a study by Petta et al. (2019), NAFLD is one of the most frequent causes of chronic liver disease worldwide, affecting around 24% of the global population. In Italy, NAFLD prevalence ranges between 20%-30%. Nonalcoholic steatohepatitis (NASH) comprises nearly 25% of NAFLD patients.

*
Park et al. (2021), in their study, found that the overall prevalence of NAFLD was 31.46%. NASH prevalence was 52%, but



This release was published on openPR.